Amir Mishan Mohammad, Rezaei Kanavi Mozhgan, Shahpasand Koorosh, Ahmadieh Hamid
Ocular Tissue Engineering Research Center, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Ophthalmic Vis Res. 2019 Oct 24;14(4):491-505. doi: 10.18502/jovr.v14i4.5459. eCollection 2019 Oct-Dec.
Tau is a microtubule-associated protein, which is highly expressed in the central nervous system as well as ocular neurons and stabilizes microtubule structure. It is a phospho-protein being moderately phosphorylated under physiological conditions but its abnormal hyperphosphorylation or some post-phosphorylation modifications would result in a pathogenic condition, microtubule dissociation, and aggregation. The aggregates can induce neuroinflammation and trigger some pathogenic cascades, leading to neurodegeneration. Taking these together, targeting pathogenic tau employing tau immunotherapy may be a promising therapeutic strategy in fighting with cerebral and ocular neurodegenerative disorders.
tau蛋白是一种与微管相关的蛋白质,在中枢神经系统以及眼神经元中高度表达,并能稳定微管结构。它是一种磷蛋白,在生理条件下会发生适度磷酸化,但其异常的过度磷酸化或一些磷酸化后修饰会导致致病状态、微管解离和聚集。这些聚集体可诱导神经炎症并引发一些致病级联反应,导致神经退行性变。综上所述,采用tau免疫疗法靶向致病性tau蛋白可能是对抗脑和眼神经退行性疾病的一种有前景的治疗策略。